>
Nephros Inc logo

NEPH - Nephros Inc Share Price

$7.76 0.0  0.1%

Last Trade - 15/10/21

Sector
Industrials
Size
Small Cap
Market Cap £57.9m
Enterprise Value £54.5m
Revenue £6.92m
Position in Universe 5709th / 7245
Bullish
Bearish
Unlock NEPH Revenue
Momentum
Relative Strength (%)
1m -3.66%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.94 2.32 3.81 5.69 10.3 8.56 11.0 16.4 +34.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Nephros, Inc.revenues increased 22% to $5M. Net loss decreased 38% to$1.8M. Revenues reflect Pathogen Detection segment increasefrom $28K to $76K. Lower net loss reflects Rental Productssegment loss decrease of 73% to $221K. Basic Earnings perShare excluding Extraordinary Items increased from -$0.33to -$0.18.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NEPH Revenue Unlock NEPH Revenue

Net Income

NEPH Net Income Unlock NEPH Revenue

Normalised EPS

NEPH Normalised EPS Unlock NEPH Revenue

PE Ratio Range

NEPH PE Ratio Range Unlock NEPH Revenue

Dividend Yield Range

NEPH Dividend Yield Range Unlock NEPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NEPH EPS Forecasts Unlock NEPH Revenue
Profile Summary

Nephros, Inc. is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. The Company operates in three segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment primarily develops and sells water purification filters. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment is focused on the development of medical device products for patients with renal disease. The Company’s products include Water Filtration Products, Pathogen Detection Systems and Specialty Renal Products (HDF System). Its subsidiary, Specialty Renal Products, Inc. (SRP), is a development-stage medical device company focused primarily on developing hemodiafiltration (HDF) technology.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated April 3, 1997
Public Since September 21, 2004
No. of Shareholders: 53
No. of Employees: 27
Sector Industrials
Industry Professional & Commercial Services
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 10,217,348
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NEPH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NEPH
Upcoming Events for NEPH
Thursday 4th November, 2021
Q3 2021 Nephros Inc Earnings Release
Thursday 4th November, 2021
Q3 2021 Nephros Inc Earnings Call
Monday 28th February, 2022 Estimate
Q4 2021 Nephros Inc Earnings Release
Frequently Asked Questions for Nephros Inc
What is the Nephros Inc share price?

As of 15/10/21, shares in Nephros Inc are trading at $7.76, giving the company a market capitalisation of £57.9m. This share price information is delayed by 15 minutes.

How has the Nephros Inc share price performed this year?

Shares in Nephros Inc are currently trading at $7.76 and the price has moved by 16.72% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Nephros Inc price has moved by -6.83% over the past year.

What are the analyst and broker recommendations for Nephros Inc?

Of the analysts with advisory recommendations for Nephros Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Nephros Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Nephros Inc next release its financial results?

Nephros Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Nephros Inc dividend yield?

Nephros Inc does not currently pay a dividend.

Does Nephros Inc pay a dividend?

Nephros Inc does not currently pay a dividend.

When does Nephros Inc next pay dividends?

Nephros Inc does not currently pay a dividend.

How do I buy Nephros Inc shares?

To buy shares in Nephros Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Nephros Inc?

Shares in Nephros Inc are currently trading at $7.76, giving the company a market capitalisation of £57.9m.

Where are Nephros Inc shares listed? Where are Nephros Inc shares listed?

Here are the trading details for Nephros Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: NEPH
What kind of share is Nephros Inc?

Based on an overall assessment of its quality, value and momentum, Nephros Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Nephros Inc share price forecast 2021?

Shares in Nephros Inc are currently priced at $7.76. At that level they are trading at 78.45% discount to the analyst consensus target price of 0.00.

Analysts covering Nephros Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.335 for the next financial year.

How can I tell whether the Nephros Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nephros Inc. Over the past six months, the relative strength of its shares against the market has been -5.09%. At the current price of $7.76, shares in Nephros Inc are trading at -6.59% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Nephros Inc PE Ratio?

We were not able to find PE ratio data for Nephros Inc.

Who are the key directors of Nephros Inc?

Nephros Inc's management team is headed by:

Arthur Amron - IND
Daron Evans - CEX
Andrew Astor - PRE
Oliver Spandow - DRC
Alisa Lask - DRC
Thomas Gwydir - DRC
Wes Lobo - OTH
Who are the major shareholders of Nephros Inc?

Here are the top five shareholders of Nephros Inc based on the size of their shareholding:

Wexford Capital LP Hedge Fund
Percentage owned: 35.54% (3.63m shares)
Concept Asset Management Investment Advisor
Percentage owned: 6.13% (626k shares)
Samjo Capital, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.37% (549k shares)
Pessin (Sandra F) Individual Investor
Percentage owned: 4.79% (489k shares)
Bard Associates Inc. Investment Advisor
Percentage owned: 2.27% (232k shares)
Similar to NEPH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.